QV Bioelectronics

About QV Bioelectronics

QV Bioelectronics is a medical device company developing a novel treatment for aggressive brain tumours. Founded in 2018 by biomedical engineer Dr. Christopher Bullock and NHS neurosurgeon Dr. Richard Fu, the company is headquartered at Alderley Park in Cheshire, UK. The founders met while Dr. Bullock was researching graphene bioelectronic devices at the University of Manchester; Dr. Fu, seeking more effective treatments for his brain tumour patients, proposed the idea of an internally delivered electric field therapy. The company's core product is the GRACE (Glioma Resection Advanced Cavity Electric Field therapy) implant. This device is designed to be implanted during surgery after a brain tumour is removed. It then delivers continuous, localized Electric Field Therapy (EFT) directly to the area where cancer cells are most likely to recur. This approach interferes with cancer cell division to slow tumour growth. Unlike existing external EFT treatments that require patients to wear a device on their head, the fully implanted GRACE system aims to provide uninterrupted therapy without disrupting a patient's daily life. The primary clinical target for GRACE is Glioblastoma (GBM), the most common and aggressive primary brain tumour in adults, which has a five-year survival rate of only 3%. QV Bioelectronics' business model focuses on bringing this Class III medical device through clinical trials to commercialization, likely involving sales to hospitals and neurosurgical centers. The company has raised significant capital to fund its development, including a £4.5 million round in January 2026 to advance the GRACE implant into its first-in-human clinical study. This funding was a mix of investment from firms like PXN Ventures and Empirical Ventures, and non-dilutive grants from the National Institute for Health and Care Research (NIHR) and Innovate UK. The company is also exploring the platform's potential for treating other cancers, including pediatric brain tumours like diffuse midline glioma (DMG).